Indian Regulatory And Industry Bodies Call For Open Dialog With Policymakers
By Akriti Seth
The Indian pharmaceutical industry’s contribution has become even more prominent in 2020 and 2021, as India has supported the global battle against the COVID-19 pandemic by managing to maintain drug supplies to almost 200 countries even during the darkest days.
IPA's Global Innovation Summit 2021 aligned with the commitment of the government to promote Indian pharmaceuticals as a globally competitive sector by ensuring access, quality and affordability of medicines in domestic and global markets.
This article supplies direct quotes from Indian prime minister Narendra Modi and secretary of India’s Department of Pharmaceuticals S Aparna on how the Summit saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.